Log in to search using one of your social media accounts:

 

Hepatocellular carcinoma: Resection vs. transplantation

(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

In conclusion, the arguments supporting moderately loosened criteria for cancer seem more valid today than in the past. Transplant oncology is likely to represent a leading field in the near future, also because comorbidities and transplant‐related causes of death are better managed and often eliminated. Liver Transplantation 2017 AASLD.
Source: Liver Transplantation - Category: Transplant Surgery Authors: Tags: Controversies in Liver Transplantation Source Type: research
ConclusionRBV‐free DAA‐combinations for the treatment of HCV‐recurrence after OLT are highly efficacious and well tolerated. Our long‐term data show that viral eradication is durable but not necessarily translated into beneficial long‐term clinical outcome.This article is protected by copyright. All rights reserved.
Source: Liver International - Category: Gastroenterology Authors: Tags: Original Article Source Type: research
Abstract Background &AimsThe outcome of compensated cirrhosis may vary considerably and cannot be predicted by routinely performed tests at present. Aim of this study was to evaluate possible predictors of clinical evolution in patients with Child‐Pugh (C‐P) class A cirrhosis due to untreatable causes by analysing clinical/biochemical/instrumental parameters evaluated at the time of diagnosis and during the subsequent long‐lasting follow‐up. MethodsTwo‐hundred‐seventy‐two consecutive C‐P class A cirrhotic patients (155 males; median age 63 years, range 34‐81) were analysed. All patients were followed...
Source: Liver International - Category: Gastroenterology Authors: Tags: Original Article Source Type: research
CONCLUSIONS: The median survival time for all patients was 106 months. The 5- and 10-year observed survival rates were 61 and 43%, respectively. The observed cumulative 5- and 10-year recurrence rates were 37 and 39%, respectively, 10-year intrahepatic and extrahepatic recurrence rates were 12 and 27%, respectively. Median survival time after diagnosis of first recurrence was 7.5 (0-120) months; 2 and 18 months for all, intra- and extrahepatic recurrence, respectively. UCSF-, up to seven-, Shanghai Fudan- or Duvoux classifications can identify patients with a cumulative 10-year recurrence rate below 20%. The pre-...
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
In conclusion, IR-induced PARP-1 up-regulation increased the hepatic recruitment of neutrophils through regulation of CXCL1/CXCR2 signaling and polarized hepatic neutrophils to proangiogenic phenotype, which further promoted HCC recurrence after transplantation. PMID: 29179487 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
A tenth of all pediatric liver transplantations (LTs) are performed for unresectable liver malignancies, especially the more common hepatoblastoma (HBL). Less understood are outcomes after LT for the rare hepatocellular carcinoma, nonhepatoblastoma embryonal tumors (EMBs), and slow growing metastatic neuroendocrine tumors of childhood. Pediatric LT is increasingly performed for rare unresectable liver malignancies other than HBL. We performed a retrospective review of outcomes after LT for malignancy in the multicenter US Scientific Registry of Transplant Recipients (SRTR; n = 677; 1987‐2015). We then revie...
Source: Liver Transplantation - Category: Transplant Surgery Authors: Tags: Original Article Source Type: research
AbstractIntroductionTumor recurrence is the most frequent cause of death after liver transplantation for hepatocellular carcinoma. We selected ten other prognostic classifications to evaluate their potential to predict the risk of recurrence after LT for HCC as compared to the Milan classification. All of the other scores have not been compared with one another in a single cohort.MethodsData of 147 consecutive patients transplanted at our department between 1996 and 2014 were analyzed and staged for morphological and functional scores of underlying liver disease. For long-term follow-up, we analyzed intrahepatic (within th...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This report shows that an MWA of an HCC in PD patients is a feasible and safe procedure. PMID: 29123005 [PubMed - in process]
Source: Peritoneal Dialysis International - Category: Urology & Nephrology Tags: Perit Dial Int Source Type: research
AbstractNon-alcoholic fatty liver disease (NAFLD) afflicts more than one third of the population in affluent societies, paralleling the dramatic escalation in global obesity prevalence. NAFLD is thus a leading cause for end-stage liver disease, cancer, and liver transplantation and an estimated 20 million patients worldwide will eventually die of their liver disease Rinella and Charlton (Hepatology2016;64:19 –22). Furthermore, NAFLD increases the risk of type 2 diabetes and cardiovascular disease. NAFLD comprises a complex disease phenotype ranging from simple steatosis, through to steatohepatitis, fibrosis, and ulti...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
Conclusion: In patients with nvHCC, serum ferritin levels are higher in non-diabetics and alcoholics.Liver Cancer 2017;6:307-312
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Transplants | Urology & Nephrology